Locally Advanced Mid/Low Rectal Cancer with Synchronous Liver Metastases

被引:22
|
作者
Vigano, Luca [1 ]
Karoui, Mehdi [2 ]
Ferrero, Alessandro [1 ]
Tayar, Claude [2 ]
Cherqui, Daniel [2 ]
Capussotti, Lorenzo [1 ]
机构
[1] Osped Mauriziano Umberto 1, Dept HPB & Digest Surg, I-10128 Turin, Italy
[2] Univ Paris 12, Hop Henri Mondor, Dept Digest & Hepatobiliary Surg, F-94010 Creteil, France
关键词
MULTIPLE COLORECTAL METASTASES; PREOPERATIVE RADIOTHERAPY; NEOADJUVANT CHEMOTHERAPY; MULTIINSTITUTIONAL ANALYSIS; SIMULTANEOUS RESECTION; 1ST-LINE TREATMENT; PRIMARY TUMOR; SURGERY; CHEMORADIATION; FLUOROURACIL;
D O I
10.1007/s00268-011-1272-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
Management of patients with T3/4 and/or N+ mid/low rectal cancer with synchronous liver metastases is not codified. The aim of this study was to analyze outcomes of our approach which consists of neoadjuvant chemotherapy or chemoradiotherapy, according to liver disease extension, followed by simultaneous rectal and liver resection. Between 2000 and 2009, 354 patients underwent hepatectomy for synchronous metastases. Thirty-six consecutive patients who underwent rectal and liver resection for metastatic T3/4 and/or N+ mid/low rectal cancer were analyzed. Liver metastases were multiple in 27 patients, bilobar in 22, and > 5 cm in six. Up-front treatment was chemotherapy in 15 patients, chemoradiotherapy in seven, chemotherapy followed by chemoradiotherapy in six, and surgery in eight (five symptomatic tumors). After chemotherapy alone (median number of cycles = 6), primary tumor response was observed in 11 patients (three complete responses). After chemoradiotherapy, only one patient had liver disease progression. Eighty-nine percent of patients underwent simultaneous rectal and hepatic resection. Mortality and morbidity rates were 2.8% (one pulmonary embolism) and 36%, respectively. After a mean follow-up of 39 months, 5-year overall and disease-free survival were 59.3 and 39.6%, respectively. Twenty-one patients had recurrence, including three pelvic recurrences (8.3%). No pelvic recurrence occurred among patients who correctly completed treatment strategy. All patients who received neoadjuvant chemoradiotherapy were alive and disease-free; 5-year overall and disease-free survival of patients receiving neoadjuvant chemotherapy were 59.3 and 25%, respectively. For patients with metastatic T3/4 and/or N+ mid/low rectal cancer, the present strategy was safe and effective. Good disease control was achieved by neoadjuvant treatments, low morbidity rates were associated with simultaneous resection, and excellent long-term outcomes with low local relapse rate were obtained.
引用
收藏
页码:2788 / 2795
页数:8
相关论文
共 50 条
  • [31] The management of rectal cancer with synchronous liver metastases: a modern surgical dilemma
    A. A. P. Slesser
    A. Bhangu
    G. Brown
    S. Mudan
    P. P. Tekkis
    [J]. Techniques in Coloproctology, 2013, 17 : 1 - 12
  • [32] How to manage a rectal cancer with synchronous liver metastases? A question of strategy
    Vendrely, V.
    Terlizzi, M.
    Huguet, F.
    Denost, Q.
    Chiche, L.
    Smith, D.
    Bachet, J. -B.
    [J]. CANCER RADIOTHERAPIE, 2017, 21 (6-7): : 539 - 543
  • [33] NEW CLASSIFICATION OF LOCALLY ADVANCED MID AND LOW RECTAL CANCER FOR SURGICAL APPROACH TO OPTIMAL OUTCOME.
    Daero, L.
    Sami, A.
    Hur, H.
    Min, B.
    Baik, S.
    Kim, N.
    [J]. DISEASES OF THE COLON & RECTUM, 2013, 56 (04) : E232 - E232
  • [34] Oncological strategies for locally advanced rectal cancer with synchronous liver metastases, interval strategy versus rectum first strategy: a comparison of short-term outcomes
    H. Salvador-Rosés
    S. López-Ben
    M. Casellas-Robert
    P. Planellas
    N. Gómez-Romeu
    R. Farrés
    E. Ramos
    A. Codina-Cazador
    J. Figueras
    [J]. Clinical and Translational Oncology, 2018, 20 : 1018 - 1025
  • [35] Oncological strategies for locally advanced rectal cancer with synchronous liver metastases, interval strategy versus rectum first strategy: a comparison of short-term outcomes
    Salvador-Roses, H.
    Lopez-Ben, S.
    Casellas-Robert, M.
    Planellas, P.
    Gomez-Romeu, N.
    Farres, R.
    Ramos, E.
    Codina-Cazador, A.
    Figueras, J.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (08): : 1018 - 1025
  • [36] Locally advanced Rectal Cancer
    Feldmann, H. J.
    [J]. ONKOLOGE, 2013, 19 (02): : 147 - 148
  • [37] Optimal surgical treatment of locally advanced low rectal cancer
    Liska, D.
    Weiser, M. R.
    [J]. MINERVA CHIRURGICA, 2010, 65 (02) : 181 - 196
  • [38] Factors associated with metachronous metastases and survival in locally advanced and recurrent rectal cancer
    Baird, D. L. H.
    Kontovounisios, C.
    Simillis, C.
    Pellino, G.
    Rasheed, S.
    Tekkis, P. P.
    [J]. BJS OPEN, 2020, 4 (06): : 1172 - 1179
  • [39] Feasibility study of a Response Surveillance Program in locally advanced mid and low rectal cancer to increase organ preservation
    Boubaddi, Mehdi
    Fleming, Christina
    Vendrely, Veronique
    Frulio, Nora
    Salut, Cecile
    Rullier, Eric
    Denost, Quentin
    [J]. EJSO, 2023, 49 (01): : 237 - 243
  • [40] The preliminary experience in simultaneous treatment of rectal cancer and synchronous liver metastases with laparoscopy
    Zhu, Ziman
    Tan, Jing-Wang
    Tan, Hua-Min
    Hu, Ben-Shun
    Chen, Ke
    Ding, Xiang-Min
    Leng, Jian-Jun
    Chen, Fei
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2013, 24 (02): : 127 - 133